Induced Pluripotent Stem Cells: Inventors turning into competitors
Requires Subscription or Fee PDF

Keywords

IPSC
Induced Pluripotent Stem Cells
Patents
Competitive Intelligence

Abstract

Induced Pluripotent Stem Cells (IPSCs) are a kind of adult cells that have been genetically reprogrammed to become different cell types. Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem cells. IPSCs technology was pioneered by Shinya Yamanaka from Kyoto University. This breakthrough has inspired researchers to start working around IPSC technology. James Thomson from University of California has developed IPS cell lines derived from Human Somatic Cells. Subsequently, he also established a large scale human IPSC manufacturing company named Cellular Dynamics International. Thus, increasing interest in the commercial exploitation of IPSCs patents has lead us to look into the patent portfolios of top three patent assignees in IPSC technology. In this study, we have discussed technological patent trends and multiple factors which reflect the competitive scenario between the top assignees of IPSC technology. Our conclusions suggest that Kyoto University led by inventor Shinya Yamanaka is the leader of IPSC technology. However, patent-product linkage analysis suggests that Cellular Dynamics International led by inventor James Thomson may surpass Kyoto University in near future.

https://doi.org/10.5912/jcb756
Requires Subscription or Fee PDF

References

Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.

Yamanaka, S., & Takahashi, K. (2011). Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells. US8058065 B2. Washington D. C: United States Patent and Trademark Office.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.

Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313-317.

Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., & Thomson, J. A. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917-1920.

https://cellulardynamics.com/about-us/

Smith, D. (2010). Commercialization challenges associated with induced pluripotent stem cell-based products. Regenerative medicine, 5(4), 593-603.

http://www.cooperativepatentclassification.org/about.html

Park, I. H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., & Daley, G. Q. (2008). Disease-specific induced pluripotent stem cells. Cell, 134(5), 877-886.

Brinn, M. W., Fleming, J. M., Hannaka, F. M., Thomas, C. B., & Beling, P. (2003, April). Investigation of forward citation count as a patent analysis method. In Systems and Information Engineering Design Symposium, 2003 IEEE (pp. 1-6). IEEE.

Yu, J., Chau, F. K., Jiang, J., Jiang, Y., & Vodyanyk, M. A. (2013). U.S. Patent No. 8,481,317. Washington, DC: U.S. Patent and Trademark Office.

Cost, G. J., Holmes, M. C., Kasahara, N., Laganiere, J., Miller, J. C., Paschon, D., & Zhang, L. (2015). U.S. Patent No. 9,222,105. Washington, DC: U.S. Patent and Trademark Office.

Neuhäusler, P., & Frietsch, R. (2013). Patent families as macro level patent value indicators: applying weights to account for market differences. Scientometrics, 96(1), 27-49.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.